GLP-1 Medications and Nutrient Deficiencies: What the Research Shows

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication or supplement. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

GLP-1 medications work, in part, by dramatically reducing how much you want to eat. That is precisely the point. But there is a downstream consequence worth understanding: when caloric intake drops by 20 to 30 percent, micronutrient intake often drops with it.

Research published in 2025 and 2026 has started mapping exactly where the nutritional gaps appear. The picture that emerges is not alarming, but it is specific. Certain nutrients show up as consistently inadequate in people using semaglutide, tirzepatide, and other GLP-1 receptor agonists. Knowing which ones, and why they matter, is useful whether you are considering treatment, already on it, or advising someone who is.

This article looks at what the current evidence shows, which nutrients appear most vulnerable, and what practical conversations with your provider might look like.

---

Why GLP-1 Medications Create Nutritional Risk

GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite through several mechanisms. They slow gastric emptying, which prolongs the sensation of fullness. They act on appetite-regulating centers in the brain, reducing food cravings and what patients often describe as "food noise." They increase satiety signals after meals. The net result is a substantial and sustained reduction in caloric intake.

In the pivotal STEP 1 trial, once-weekly semaglutide reduced body weight by an average of 14.9 percent over 68 weeks (PMID 33567185). A 2017 study examining appetite and food intake effects of semaglutide in people with obesity found significant reductions in energy intake and alterations in food preferences, with participants consuming fewer calories and reporting lower appetite ratings throughout the day (PMID 28266779). Similar patterns are seen with tirzepatide.

The problem is straightforward: when you eat substantially less, you are also taking in fewer vitamins, minerals, protein, and fiber. If the food you do eat is not nutritionally dense, gaps can develop and widen over months of treatment.

A 2026 narrative review in *Clinical Obesity*, covering six studies encompassing more than 480,000 adults on GLP-1 receptor agonist therapy, found that nutritional deficiencies within 12 months of treatment were more common than previously recognized (PMID 41549912). Vitamin D deficiency was the most frequently observed abnormality, appearing in 7.5 percent of patients at six months and climbing to 13.6 percent at twelve months. Iron, calcium, thiamine, and other B vitamins also appeared in the deficiency pattern.

---

The Specific Nutrients Research Highlights

Vitamin D

Vitamin D deficiency is already common in the general adult population, particularly in northern latitudes or among people who spend limited time outdoors. GLP-1 medication use appears to compound this risk.

The narrative review noted vitamin D as the most consistent deficiency finding across the studies examined (PMID 41549912). Vitamin D is primarily obtained through sun exposure, with smaller amounts from food sources like fatty fish, egg yolks, and fortified products. When appetite suppression reduces overall food variety and quantity, dietary vitamin D intake can fall further. Additionally, vitamin D is fat-soluble and absorbed alongside dietary fat; meals that are smaller and lower in fat may reduce absorption.

Vitamin D plays a role in calcium absorption, immune function, muscle function, and mood regulation. Deficiency over time has been associated with bone density loss, immune dysfunction, and fatigue, outcomes that are relevant for people actively managing their weight and physical health.

Protein

Protein does not show up as a "deficiency" in the traditional micronutrient sense, but it is arguably the most clinically important nutritional concern in GLP-1 medication users.

A 2025 cross-sectional study published in *Frontiers in Nutrition* examined dietary intake in 69 adults using GLP-1 receptor agonists (predominantly semaglutide and tirzepatide) through three-day food records (PMID 40352260). While protein intake as a percentage of total calories was within acceptable ranges, protein intake measured in grams per kilogram of body weight fell significantly below daily needs. For someone in active weight loss, protein needs are elevated precisely because the body must be protected from breaking down lean muscle tissue for energy.

Muscle loss during weight loss is a known concern with any caloric restriction approach. GLP-1 medications do not appear to cause unusual muscle loss compared to calorie restriction alone, but the volume of caloric reduction they enable is significant. People eating substantially less need to be intentional about protein density in the food they do eat. See the related discussion in [Muscle Preservation During GLP-1 Therapy](/resources/muscle-preservation-glp1-therapy) and [Protein Intake on GLP-1 Medications](/resources/protein-intake-glp1-medications).

Iron

Iron deficiency is the most common nutritional deficiency worldwide, and GLP-1 medication use may increase the risk. The 2025 *Frontiers in Nutrition* study found that approximately 64 percent of GLP-1 receptor agonist users consumed less than the estimated average requirement for iron (PMID 40352260). The gap was meaningful, not marginal.

Iron is found in red meat, poultry, shellfish, legumes, and fortified cereals. When appetite suppression reduces meat consumption specifically, which is common given the caloric density of meat and the early satiety that accompanies GLP-1 use, iron intake can fall. The slower gastric emptying that accompanies GLP-1 therapy may also affect iron absorption at the level of the duodenum, though this is less well-studied.

Iron deficiency can produce fatigue, reduced exercise tolerance, and impaired cognitive function, symptoms that can be easily misattributed to weight loss itself or medication adjustment.

<img src="/images/articles/semaglutide-hair-loss-protein-inline.jpg" alt="Close-up of a balanced meal plate with protein-rich foods and colorful vegetables, representing nutritional density on GLP-1 therapy, Prescriva lifestyle tone" />

Calcium

The 2025 cross-sectional study found that approximately 72 percent of GLP-1 medication users consumed below the recommended dietary allowance for calcium (PMID 40352260). Calcium adequacy matters for bone density, muscle contraction, and nerve function. It is particularly important in the context of weight loss, because bone density can decline modestly during rapid weight loss regardless of the method used.

Calcium is abundant in dairy products, leafy greens like kale and bok choy, fortified plant milks, and canned fish with bones. When appetite suppression compresses overall food volume and variety, calcium-rich foods may be displaced by simpler, lower-nutrient options.

B Vitamins, Magnesium, and Other Micronutrients

The broader picture from the *Clinical Obesity* review shows a pattern of subclinical micronutrient inadequacy across multiple vitamins and minerals (PMID 41549912). Thiamine (vitamin B1), which is critical for nerve function and energy metabolism, was among the B vitamins flagged. Magnesium, potassium, vitamin A, vitamin C, vitamin E, and choline also appeared below recommended intakes in the *Frontiers in Nutrition* cross-sectional data (PMID 40352260).

These are not dramatic, acute deficiencies in most cases. They are the kind of slow inadequacies that accumulate over months and can show up as fatigue, muscle cramping, difficulty concentrating, or other nonspecific symptoms that are easy to overlook or attribute to other causes.

Fiber

Fiber is consistently underconsumed in the general population, and GLP-1 medication use does not improve this. The cross-sectional study found average fiber intake of 14.5 grams per day in GLP-1 users, well below the recommended 25 to 38 grams per day depending on age and sex (PMID 40352260). Fiber supports gut microbiome health, blood sugar regulation, cholesterol management, and satiety. It is found in vegetables, fruits, legumes, and whole grains: foods that require appetite and deliberate food choices to consume in meaningful quantities.

---

Learning from Metabolic Surgery Research

Bariatric surgery, which produces similar or greater degrees of caloric restriction and weight loss, has a much longer evidence base on nutritional consequences. Patients who undergo procedures like Roux-en-Y gastric bypass or sleeve gastrectomy routinely develop deficiencies in vitamin B12, iron, vitamin D, calcium, and other nutrients, and post-surgical protocols universally include long-term micronutrient supplementation and monitoring.

A 2025 review in *Nutrients* examined whether similar monitoring frameworks should apply to GLP-1 medication users (PMC12693348). The authors found meaningful parallels in the mechanisms driving nutrient risk and argued that, while GLP-1 users do not face the same degree of malabsorption as some surgical procedures, the degree of caloric reduction warrants a similar mindset around nutritional awareness, supplementation, and monitoring.

---

What This Means Practically

The research does not support alarm, but it does support attention.

Several practical considerations emerge from the evidence:

Food quality matters more, not less. When eating volume decreases, each meal needs to carry more nutritional weight. Prioritizing protein-first eating, including non-starchy vegetables, incorporating calcium-rich foods, and including healthy fats to support fat-soluble vitamin absorption becomes more important, not less, during GLP-1 treatment.

Supplementation conversations belong in your care plan. Many providers recommend a high-quality multivitamin as baseline support during GLP-1 treatment. Some patients may benefit from targeted supplementation based on baseline labs or risk factors. This is a provider-level conversation informed by bloodwork, dietary history, and individual health circumstances. Do not start or stop supplements without discussing them with your provider.

Baseline and follow-up labs are valuable. Your provider may recommend checking vitamin D, iron, ferritin, B12, calcium, and a comprehensive metabolic panel at baseline and periodically during treatment. These measurements can identify subclinical deficiencies before they become symptomatic and guide targeted supplementation if needed.

Protein targets are worth tracking. General guidance for adults managing weight loss while preserving lean mass typically falls in the range of 1.2 to 1.6 grams of protein per kilogram of body weight per day. This is higher than standard population recommendations and usually requires deliberate planning, especially when appetite is suppressed.

---

A Note on Research Limitations

The evidence base here is still developing. Most studies to date are observational or cross-sectional, meaning they capture a snapshot of nutrient intake without establishing causation or tracking outcomes over time. The largest systematic review had only six qualifying studies at the time of publication, reflecting how recent this research area is (PMID 41549912). Randomized controlled trials with pre-planned nutritional monitoring endpoints in GLP-1 medication users remain limited.

This does not mean the findings are unreliable. It means the full picture is still coming into focus. Providers and patients should treat current evidence as informative, not definitive, and expect the guidance to be refined as longer-term data becomes available.

---

Is This Relevant to Compounded GLP-1 Medications?

The nutritional research summarized here is based on studies of FDA-approved semaglutide and tirzepatide formulations. Compounded semaglutide and compounded tirzepatide contain the same active compounds, and the appetite-suppression and caloric-intake mechanisms are the same. The nutritional considerations are therefore directly applicable. However, compounded medications are not FDA-approved, are not reviewed by the FDA for safety, efficacy, or quality, and are not equivalent to or interchangeable with branded products. All medical decisions, including supplementation, should be made in coordination with your licensed healthcare provider.

---

Summary

Research published in 2025 and 2026 confirms that GLP-1 medications, by significantly reducing caloric intake, can create meaningful gaps in micronutrient intake. Vitamin D is the most consistently identified deficiency. Protein, iron, calcium, fiber, magnesium, and multiple B vitamins are also frequently inadequate in GLP-1 medication users.

These gaps are manageable with awareness, food quality, and provider-guided monitoring. They are worth discussing openly in your care relationship, particularly at the start of treatment and at regular intervals during it.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication or supplement.

Compounding Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as, equivalent to, or interchangeable with Mounjaro or Zepbound.

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.